Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events
Introduction. Afatinib is a first-line treatment option for patients with an advanced nonsmall cell lung cancer (NSCLC) expressing an epidermal growth factor receptor (EGFR) activating mutation. This study aimed to evaluate the association between early adverse events induced by afatinib and overall...
Main Authors: | Jessica M. Logan, Doug A. Brooks, Andrew Rowland, Michael J. Sorich, Ashley M. Hopkins |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2021-01-01
|
Series: | Journal of Oncology |
Online Access: | http://dx.doi.org/10.1155/2021/2414897 |
Similar Items
-
Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data
by: Ashley M. Hopkins, et al.
Published: (2019-06-01) -
Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials
by: Ashley M. Hopkins, et al.
Published: (2018-10-01) -
Adverse Events of Afatinib as First-line Treatment for Five Cases of Advanced
Lung Adenocarcinoma and Review of Literature
by: Hong TAO, et al.
Published: (2014-04-01) -
Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
by: Ashley M Hopkins, et al.
Published: (2020-06-01) -
Role of gender in the survival of surgical patients with nonsmall cell lung cancer
by: Nóris C Scaglia, et al.
Published: (2013-01-01)